课题基金 / 基金详情

BMY-42215 (15-DEOXYSPERGUALIN TRIHYDROCHLORIDE) IN RHEUMATOID ARTHRITIS

BMY-42215 (15-DEOXYSPERGUALIN TRIHYDROCHLORIDE) IN RHEUMATOID ARTHRITIS
BMY-42215（15-脱氧精胍菌素三盐酸盐）治疗类风湿性关节炎
批准号：
5215649
负责人：
LARRY W MORELAND
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5215649
关键词：
antirheumatic agents clinical research clinical trial phase I drug screening /evaluation human subject human therapy evaluation rheumatoid arthritis skeletal disorder chemotherapy

项目摘要

项目成果

LARRY W MORELAND的其他基金

相似基金

相关文献

中文摘要
翻译
给予BMY-42215-1（15-脱氧桔瓜林三盐酸盐）
英文摘要
BMY-42215-1 (15-Deoxyspergualin Trihydrochloride) was administered to nine patients with rheumatoid arthritis in a Phase I pilot study to determine the efficacy and safety. The study closed on 01-04-95 and no significant or unexpected adverse events were reported. Preliminary findings regarding the effectiveness of this study are not available at this time.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
ANTIBODIES AND MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH AUTOIMMUNE DISEASES
Rheumatoid Arthritis Induction Trial (RAITMAT)
AUTOIMMUNE BIOMARKERS COLLABORATIVE NETWORK
海外基金